A Single Center, Prospective Study Evaluating the Anti-fibrotic Effect of Combination Therapy of Peginterferon Alpha-2a Plus Ribavirin in Patients With Chronic Hepatitis C, Based on Histologic Changes and Noninvasive Fibrosis Assessments
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 10 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 13 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.